KMT2B Mutation

CI-VAR-00002829Explore in graph →CIViC 5261

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
KMT2C Mutation OR KMT2D mutation OR KMT2A Mutation OR KMT2B Mutation	Immune Checkpoint Inhibitor	Predictive	B	Supports Sensitivity Response	2	submitted	EID12593 In a retrospective pan-cancer analysis of four immune checkpoint therapy (ICT)–treated cohorts (melanoma n = 287; NSCLC n = 131; total n = 418), KMT2 family mutations were associated with improved ICT… (full text at CIViC) PMID 33653367 · Zhang et al., 2021 · Open in CIViC	civic
Melanoma1
KMT2C Mutation OR KMT2D mutation OR KMT2A Mutation OR KMT2B Mutation	Immune Checkpoint Inhibitor	Predictive	B	Supports Sensitivity Response	2	submitted	EID12592 In a retrospective pan-cancer analysis of four immune checkpoint therapy (ICT)–treated cohorts (melanoma n = 287; NSCLC n = 131; total n = 418), KMT2 family mutations were associated with improved ICT…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.